Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) Gross Margin (2016 - 2025)

Guided Therapeutics' Gross Margin history spans 15 years, with the latest figure at 56.67% for Q3 2025.

  • For Q3 2025, Gross Margin changed N/A year-over-year to 56.67%; the TTM value through Sep 2025 reached 62.36%, up 973.0%, while the annual FY2024 figure was 28.57%, 816.0% down from the prior year.
  • Gross Margin for Q3 2025 was 56.67% at Guided Therapeutics, down from 67.52% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q2 2021 and bottomed at 200.0% in Q4 2024.
  • The 5-year median for Gross Margin is 66.67% (2024), against an average of 33.25%.
  • The largest annual shift saw Gross Margin crashed -27167bps in 2021 before it soared 22105bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 68.33% in 2021, then soared by 46bps to 100.0% in 2022, then crashed by -50bps to 50.0% in 2023, then crashed by -500bps to 200.0% in 2024, then soared by 128bps to 56.67% in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Gross Margin are 56.67% (Q3 2025), 67.52% (Q2 2025), and 200.0% (Q4 2024).